International journal of cancer research最新文献

{"title":"Chloroform Extract of Solanum trilobatum Inhibits the Progress of Ehrlich Ascites Carcinoma in Mice","authors":"H. Sini, K. Devi, K. G. Nevin","doi":"10.3923/IJCR.2016.17.28","DOIUrl":"https://doi.org/10.3923/IJCR.2016.17.28","url":null,"abstract":"This study was initiated to evaluate the modulating effect of chloroform extract of Solanum trilobatum (CST) on Ehrlich Ascites Carcinoma (EAC) in mice. In vitro cytotoxicity of CST on Ehrlich Ascites Cells (EAC) and Human Leukemic cells (HL-60 cells) were evaluated using trypan blue staining. To study the in vivo effect of CST, tumors were introduced into experimental animals by intraperitoneal injection. Animals were treated with CST (400 mg kgG b.wt., after 24 h and 7 days of tumor inoculation for five alternate days. Cisplatin, an antitumor drug (2 mg kgG b.wt.,) was used as a positive control starting from first and the seventh day of tumor inoculation, respectively. After the experimental period, antitumor parameters (ascitic tumor volume, mean survival time and viability of tumor cells), hematological studies and biochemical parameters (activities of SGOT, SGPT, ALP and LDH) were measured. Results showed that CST strongly inhibited the growth of HL-60 and EAC cell line in in vitro condition. In in vivo conditions, administration of CST reduced the tumor volume and the viability of tumor cells as well as increased the mean survival time of EAC inoculated mice. Activities of liver enzymes were found to be restored by the administration of CST. Histopathological examination showed that CST was capable of reducing the damage caused to the liver by the excessive tumor growth. The cytotoxic and antitumor effect demonstrated by this study supported the fact that the antioxidant components present in CST may be a promising source of antitumor compounds for managing different types of cancer.","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"663 1","pages":"17-28"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77028898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting Bone Marrow to Potentiate the Anti-Tumor Effect of Tyrosine Kinase Inhibitor in Preclinical Rat Model of Human Glioblastoma.","authors":"S Shaaban,&nbsp;M Alsulami,&nbsp;S A Arbab,&nbsp;R Ara,&nbsp;A Shankar,&nbsp;A Iskander,&nbsp;K Angara,&nbsp;M Jain,&nbsp;H Bagher-Ebadian,&nbsp;B R Achyut,&nbsp;A S Arbab","doi":"10.3923/ijcr.2016.69.81","DOIUrl":"https://doi.org/10.3923/ijcr.2016.69.81","url":null,"abstract":"<p><p>Antiangiogenic agents caused paradoxical increase in pro-growth and pro-angiogenic factors and caused tumor growth in glioblastoma (GBM). It is hypothesized that paradoxical increase in pro-angiogenic factors would mobilize Bone Marrow Derived Cells (BMDCs) to the treated tumor and cause refractory tumor growth. The purposes of the studies were to determine whether whole body irradiation (WBIR) or a CXCR4 antagonist (AMD3100) will potentiate the effect of vatalanib (a VEGFR2 tyrosine kinase inhibitor) and prevent the refractory growth of GBM. Human GBM were grown orthotopically in three groups of rats (control, pretreated with WBIR and AMD3100) and randomly selected for vehicle or vatalanib treatments for 2 weeks. Then all animals underwent Magnetic Resonance Imaging (MRI) followed by euthanasia and histochemical analysis. Tumor volume and different vascular parameters (plasma volume (v_p), forward transfer constant (K^trans), back flow constant (k_ep), extravascular extracellular space volume (v_e) were determined from MRI. In control group, vatalanib treatment increased the tumor growth significantly compared to that of vehicle treatment but by preventing the mobilization of BMDCs and interaction of CXCR4-SDF-1 using WBIR and ADM3100, respectively, paradoxical growth of tumor was controlled. Pretreatment with WBIR or AMD3100 also decreased tumor cell migration, despite the fact that ADM3100 increased the accumulation of M1 and M2 macrophages in the tumors. Vatalanib also increased K^trans and v_e in control animals but both of the vascular parameters were decreased when the animals were pretreated with WBIR and AMD3100. In conclusion, depleting bone marrow cells or CXCR4 interaction can potentiate the effect of vatalanib.</p>","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"12 2","pages":"69-81"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4945124/pdf/nihms749728.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34569464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemopreventive Potential of Sunflower Seeds in a Human Colon Cancer Cell Line","authors":"L. Smith, J. Patterson, L. Walker, M. Verghese","doi":"10.3923/IJCR.2016.40.50","DOIUrl":"https://doi.org/10.3923/IJCR.2016.40.50","url":null,"abstract":"Sunflower Seed (SS) (Helianthus annuus L.) is an oil seed crop that is a good source of protein. The objective of this study was to investigate the chemopreventive potential of SS extracts (defatted and whole) through determination of phytochemical content, antioxidative potential and cytotoxic effects on Caco-2 cells. Phytochemical (total phenolic, total flavonoid) content, Trolox Equivalent Antioxidant Capacity (TEAC), free radical-scavenging ability of 2, 2-diphenyl-1-picrylhydrazyl (DPPH) and Ferric Reducing Antioxidant Potential (FRAP) were determined according to standard protocol. Lactate dehydrogenase (LDH) release (cytotoxicity assay) was used to measure in vitro cell damage of Caco-2 colon cancer cells. Activity of cellular detoxification and antioxidant enzymes was determined with selected concentrations of SS extracts (25, 50 and 100 μg mLG). Apoptotic activity was assessed through the activity of Caspase-3 and DNA fragmentation ELISA. Anti-inflammatory activity was assessed through Cox-2. Total phenolic content was 62.76±7.37 mg GAE/100 g and total flavonoid content of SS extracts was 26.49 mg CE/100 g. Antioxidant potential: TEAC was 858.83±97.7 μmol TE/100 g, DPPH radical scavenging (IC50 value) was 8 mg mLG 1 and FRAP was 14.13±1.25 mmol/Fe/g for SS extracts. The LDH release (%), cytotoxicity, after 12 and 24 h incubation with SS extracts was 39.8 and 53.1% at 25 μg mLG. Caspase-3 activity was 18.60±0.19, Cox-2 was 0.28 U mLG and DNA fragmentation ELISA was 0.47 EF at 24 h incubation of extract at 100 μg mLG. The results for the antioxidant and detoxification enzymes yielded were: GST (0.0017±0.001 nmol minG mLG), CAT 24.1±0.13 U mgG, GPx 30.4±0 nmol minG mLG, SOD 313.3±3.98 U mLG and GSH 13.7± nmol mLG. Results of this study revealed high phenolic and flavonoid content and suggested cytotoxic and antioxidative potential of SS extracts as a chemopreventive agent.","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"20 1","pages":"40-50"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87388140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Epithelial Ovarian Carcinoma in India: A Case Control Study in Low-Incidence Population","authors":"S. Shanmughap, G. Senthilkum, S. Arun, B. Das, K. Natarajase","doi":"10.3923/IJCR.2016.61.68","DOIUrl":"https://doi.org/10.3923/IJCR.2016.61.68","url":null,"abstract":"","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"4 6","pages":"61-68"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72593348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytotoxic and Apoptotic Effects of Sprouted and Non-sprouted Lentil, Green and Yellow Split-peas","authors":"K. Busambwa, R. Sunkara, N. Diby, R. O. Okyne, J. Boateng, M. Verghese","doi":"10.3923/IJCR.2016.51.60","DOIUrl":"https://doi.org/10.3923/IJCR.2016.51.60","url":null,"abstract":"","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"124 1","pages":"51-60"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87829737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Implications of Microarray in Cancer Medicine","authors":"J. Kang","doi":"10.3923/IJCR.2015.150.158","DOIUrl":"https://doi.org/10.3923/IJCR.2015.150.158","url":null,"abstract":"Cancers are associated with an array of orchestrated genetic changes and the identification of changes causally related to the carcinogenic process. To elucidate the mechanism of cancer carcinogenesis, it is necessary to reconstruct molecular events at each level. Microarray technology is a versatile platform that allows rapid genetic analysis to take place on a genome-wide scale and has revolutionized to evaluate genetic markers and changes in cancer genetics. Since, their development in the mid-1990s, these technologies have become a key tool in the fight against cancer. Microarray data have led to the identification of molecular subclasses of solid tumors characterized by distinct oncogenic pathways, as well as the development of multigene prognostic or predictive models equivalent or superior to those of established clinical parameters. Currently, several genomic aberrations discovered by these assays are presently being used as predictive markers for cancer treatment with targeted therapeutics. But how do microarrays work and just how have they been used in cancer diagnosis and treatment thus far? Here, we presented a summary of the main applications of microarrays in the field of targeted therapies of cancer and discussed their potential in clinical implementation.","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"54 1","pages":"150-158"},"PeriodicalIF":0.0,"publicationDate":"2015-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85210842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumoricidal Property of Normoxia and Hypoxia Cell-Free Lysate ofWharton’s Jelly-Mesenchymal Stem Cells Toward Various CancerCells","authors":"W. Widowati, L. Wijaya, D. Agustina, Harry Murti, N. Fauziah, S. Sumitro, M. Widodo, I. Bachtiar","doi":"10.3923/IJCR.2015.186.196","DOIUrl":"https://doi.org/10.3923/IJCR.2015.186.196","url":null,"abstract":"Cancer is one of the leading causes of mortality and morbidity throughout the world. Since \u0000there are still some problems related to the conventional therapies for cancer treatment, it is \u0000critical to explore new more efficient therapy strategies. Mesenchymal Stem Cells (MSCs) are one \u0000of powerful tools for tissue engineering for regenerative medicine, as recent research aims to utilize \u0000MSCs for anti-cancer treatment. Our previous research demonstrated that Conditioned Medium \u0000from Whartons’ Jelly MSCs (WJ-MSCs-CM) significantly lowered cancer proliferation of various \u0000cancer cell lines. This research was performed to evaluate the tumoricidal property of cell lysate \u0000from WJ-MSCs from normoxia (WJMSCs-norCL) and hypoxia-treated WJMSCs (WJMSCs-hypoCL) \u0000on the proliferation of human cancer cells, including cervical (HeLa), liver (HepG2), ovarian \u0000(SKOV3) and oral squamous (HSC3) cancer cell lines compared to normal cells including \u0000mouse fibroblast (NIH3T3), human Mesenchymal Stem Cells (hMSCs), human fibroblast. The \u0000WJMSCs-norCL and WJMSCs-hypoCL have cytotoxic activity, reduce proliferation of various \u0000cancer cell lines with minimum inhibitory concentration (IC50) 21.094-95.928 μg mLG1 and no \u0000cytotoxic to normal cells with IC50 409, 191-629, 799.738 μg mLG1. The WJMSCs-norCL and \u0000WJMSCs-hypoCL inhibit proliferation in various cancer cell lines and are not toxic for normal cells.","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"16 1","pages":"186-196"},"PeriodicalIF":0.0,"publicationDate":"2015-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84348537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Myeloid Leukemia in Patient with Local Recurrence Colon Cancer: A Case Report","authors":"M. Payandeh, Edris Sadeghi, M. Sadeghi, F. Falsafi, S. Madani","doi":"10.3923/IJCR.2015.197.200","DOIUrl":"https://doi.org/10.3923/IJCR.2015.197.200","url":null,"abstract":"Chronic Myeloid Leukemia (CML) is a chronic disease that about 50% of patients are more than 60 years old and about 50% of patients are asymptomatic. In this study, It is reported that, a case of CML after colon cancer chemotherapy in a 52 year old male from Iran who diagnosed locally advanced poorly differentiation colon adenocarcinoma with extension to prostate for him that had undergone to chemotherapy induction, then chemoradiation with surgery for mid-rectal cancer in the follow-up with picture of local recurrence and rectovesical-fistula. His first regimen in induction chemotherapy phase been oxaliplatin plus capecitabine and follow with chemoradiation for one month. The KRAS was mutation for the patient. He treated with combination of capecitabine with bevacizumab. After new progression he treated with Xeloda+irinotecan regimen. In routine follow-up in complete blood count analysis, It was found that shift to left with immature granulocytopoietic forms. Analysis by RT-PCR peripheral blood showed that Philadelphia chromosome was positive, so CML was diagnosed for him and was add imatinib to his treatment policy. Combination of oxaliplatin and irinotecan can be carcinogenic even they can probably create secondary hematological malignancy like CML and also irradiation can be other risk factor in patients with colorectal cancer following chemotherapy.","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"14 1","pages":"197-200"},"PeriodicalIF":0.0,"publicationDate":"2015-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80393237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical Cancer: A Perspective on Recent Patents","authors":"L. J. Tharappel, Parmi Patel, Ginpreet Kaur, V. Addepalli","doi":"10.3923/IJCR.2015.159.163","DOIUrl":"https://doi.org/10.3923/IJCR.2015.159.163","url":null,"abstract":"","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"64 1","pages":"159-163"},"PeriodicalIF":0.0,"publicationDate":"2015-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76989802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human Epididymis Protein 4 (HE4) mRNA as a Prognostic Marker in Ovarian Tumors in Relation to RMI and CA125","authors":"M. Yehia, A. Mansour, S. Mekawy","doi":"10.3923/IJCR.2015.175.185","DOIUrl":"https://doi.org/10.3923/IJCR.2015.175.185","url":null,"abstract":"Human Epididymis protein 4 (HE4) has recently been shown to improve the sensitivity and specificity of Epithelial Ovarian Cancer (EOC) diagnosis but its function in cancer cells is not clear. We evaluated HE4 expression, RMI and CA125 serum level as diagnostic tools of primary ovarian cancer in Egyptian women. The HE4 gene expression was evaluated by real time PCR in ovarian cancer of 50 Egyptian women. Ovarian cancer tissues were studied for the detection of the gene expression of HE4 by Quantitative Real Time PCR (Q RT-PCR). Serum Human cancer antigen 125 (CA 125) was measured in the serum of all participants of the study using immune sorbent assay (ELISA). The HE4 showed significant difference among ovarian malignant tumors patients compared to the control subjects (p<0.01). The best cutoff value 0.053 at which HE4 sensitivity was 92% and specificity was 96%. There was a significance correlation between HE4, RMI and CA125 in all patients of the study (p#0.01 for both). The mRNA expression of HE4 was significantly high versus the control group in early stages and low grades of the disease (p = 0.00, 0.01, respectively). As well as, there was Increased HE4 expression in the late stages of the disease suggesting that it may be associated with poor prognosis as well. The HE4 could be considered as a good prognostic marker for ovarian cancer that increases the sensitivity of the CA 125 to absolute value without affection of CA125 accuracy and its positive predictive value.","PeriodicalId":90856,"journal":{"name":"International journal of cancer research","volume":"126 1","pages":"175-185"},"PeriodicalIF":0.0,"publicationDate":"2015-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80382304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}